Tumor-restricted activation of Vγ9Vδ2 T cells via bispecific Evobodies: a novel strategy for safe and potent immunotherapy in ovarian cancer
Thus, Evobodies represent a novel, first-in class of biologics for solid tumor treatment and are well-suited for further clinical development.
Authors
- Matthias Peipp (ORCID: https://orcid.org/0000-0002-5088-3804)
- Steffen Krohn
- Dorothee Winterberg (ORCID: https://orcid.org/0009-0009-9840-8074)
- Daniela Wesch (ORCID: https://orcid.org/0000-0001-6509-208X)
- Christoph Baumann (ORCID: https://orcid.org/0000-0002-1263-5594)
- Klaus‐Peter Künkele
- Hans‐Heinrich Oberg (ORCID: https://orcid.org/0000-0002-8354-3494)
- Dirk Bauerschlag (ORCID: https://orcid.org/0000-0001-8157-6121)
- Malte Deseke
Institutions
- Christian-Albrechts-Universität zu Kiel (DE)
- University Hospital Schleswig-Holstein (DE)
- Jena University Hospital (DE)
- Everbright International (China) (CN)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1628501
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 0.00